Work

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5663

Authors: Mazyar Shadman, Ian Flinn, Moshe Levy, Steven Papish, John M. Burke, Jamal Misleh, Jennifer Cultrera, Habte Yimer, Edwin Kingsley, Charles Farber, James D'Olimpio, Nan Sun, Adam Idoine, Jeff Sharman

Institutions: University of Washington, Fred Hutch Cancer Center, Tennessee Oncology, Rocky Mountain Cancer Centers, Medical Oncology Hematology Consultants, Florida Cancer Specialists & Research Institute, Comprehensive Cancer Centers of Nevada, Morristown Medical Center, Willamette Valley Cancer Institute and Research Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417018564

Cites:

Cited by:

Related to: